Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Revenue: 2009-2025

Historic Revenue for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $200,000.

  • Northwest Biotherapeutics' Revenue fell 43.98% to $200,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $937,000, marking a year-over-year decrease of 41.29%. This contributed to the annual value of $1.4 million for FY2024, which is 28.47% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Revenue stood at $200,000, which was up 52.67% from $131,000 recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Revenue high stood at $880,000 for Q1 2023, and its period low was -$1.2 million during Q4 2021.
  • Over the past 3 years, Northwest Biotherapeutics' median Revenue value was $357,000 (recorded in 2024), while the average stood at $365,455.
  • Within the past 5 years, the most significant YoY rise in Northwest Biotherapeutics' Revenue was 20,700.00% (2021), while the steepest drop was 329.22% (2021).
  • Over the past 5 years, Northwest Biotherapeutics' Revenue (Quarterly) stood at -$1.2 million in 2021, then skyrocketed by 151.78% to $597,000 in 2022, then decreased by 25.46% to $445,000 in 2023, then slumped by 48.09% to $231,000 in 2024, then plummeted by 43.98% to $200,000 in 2025.
  • Its Revenue stands at $200,000 for Q3 2025, versus $131,000 for Q2 2025 and $375,000 for Q1 2025.